OFIX

SEC source: 0001209191-17-044659 · doc4.xml · derivative · entry 2

Bianchi Davide · CIK 0001587881 · President Extremity Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,409

Underlying: Common Stock · 10,409 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044659 · doc4.xml · nonDerivative · entry 1

Bianchi Davide · CIK 0001587881 · President Extremity Fixation

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,603

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044658 · doc4.xml · derivative · entry 3

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,508

Underlying: Common Stock · 6,508 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-17-044658 · doc4.xml · derivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,355

Underlying: Common Stock · 11,355 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044658 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,522

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044657 · doc4.xml · derivative · entry 3

Elting Kimberley A. · CIK 0001605209 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,050

Underlying: Common Stock · 7,050 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-17-044657 · doc4.xml · derivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,301

Underlying: Common Stock · 12,301 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044657 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,125

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044656 · doc4.xml · derivative · entry 3

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,592

Underlying: Common Stock · 7,592 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-17-044656 · doc4.xml · derivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,248

Underlying: Common Stock · 13,248 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044656 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,096

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044655 · doc4.xml · derivative · entry 3

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,369

Underlying: Common Stock · 30,369 shares

Expires 2020-07-03

F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.

SEC source: 0001209191-17-044655 · doc4.xml · derivative · entry 2

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,990

Underlying: Common Stock · 52,990 shares

Expires 2027-07-03

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044655 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,786

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017.

SEC source: 0001209191-17-044654 · doc4.xml · nonDerivative · entry 1

MARKS LILLY · CIK 0001645735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,029

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director.

SEC source: 0001209191-17-044653 · doc4.xml · nonDerivative · entry 1

Sainz Maria · CIK 0001437768 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,812

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director.

SEC source: 0001209191-17-044652 · doc4.xml · nonDerivative · entry 1

FAULSTICK LUKE T · CIK 0001248184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,529

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director.

SEC source: 0001209191-17-044651 · doc4.xml · nonDerivative · entry 1

Lukianov Alexis V · CIK 0001289410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,579

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director.

SEC source: 0001209191-17-044650 · doc4.xml · nonDerivative · entry 1

Paolucci Michael E · CIK 0001599463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,529

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director.

SEC source: 0001209191-17-044649 · doc4.xml · nonDerivative · entry 1

Hinrichs James F. · CIK 0001506974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,638

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director.

SEC source: 0001209191-17-044647 · doc4.xml · nonDerivative · entry 1

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,394

F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director.

SEC source: 0001209191-17-042018 · doc4.xml · derivative · entry 3

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,300 shares

Expires 2017-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-042018 · doc4.xml · nonDerivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,614

SEC source: 0001209191-17-042018 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-042017 · doc4.xml · derivative · entry 3

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,667 shares

Expires 2017-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-042017 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,867

SEC source: 0001209191-17-042017 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,422

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-155385 · doc4.xml · derivative · entry 1

Lukianov Alexis V · CIK 0001289410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2026-12-13

F1 · derivative.exercise_date: These stock options vest in 25% increments on each of December 13, 2017, 2018, 2019 and 2020.

SEC source: 0001209191-16-149393 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,681

F1 · kind: The sale of the shares reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on September 15, 2016.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.56 to $36.41, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-16-149393 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,219

F1 · kind: The sale of the shares reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on September 15, 2016.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $36.63, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-16-148656 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President Biostim

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,534

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, November 4, 2016.

SEC source: 0001209191-16-143017 · doc4.xml · derivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2026-09-26

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, September 26, 2016.

SEC source: 0001209191-16-143017 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,600

F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, September 26, 2016.